CTI BioPharma Net income (Q3, 2018)-14.8 M

CTI BioPharma EBIT (Q3, 2018)-14.8 M

CTI BioPharma Cash, 30-Sep-201852.9 M

CTI BioPharma EV16.5 M

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Revenue | 34.7m | 60.1m | 16.1m | 57.4m | 25.1m |

| 73% | (73%) | 256% | ||

## Cost of goods sold | 895.0k | ||||

## Gross profit | 59.2m | ||||

| 99% | ||||

## R&D expense | 33.6m | 76.6m | 65.0m | 32.9m | |

## General and administrative expense | 42.3m | 54.0m | 45.3m | 31.4m | |

## Operating expense total | 75.9m | 132.8m | 110.3m | 64.3m | |

## EBIT | (41.5m) | (86.2m) | (116.7m) | (49.2m) | (39.5m) |

| (120%) | (144%) | (724%) | (86%) | (157%) |

## Interest expense | 1.0m | 1.9m | 2.1m | 2.6m | 1.9m |

## Net Income | (49.6m) | (94.2m) | (122.6m) | (52.0m) | (45.0m) |

- Source: SEC Filings

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 362.0k | 1.4m | 1.3m | 39.5m | 2.7m | 1.1m | 964.0k | 36.5m | 7.4m | 4.4m | 754.0k | 22.2m | 1.7m | 10.5m | 613.0k | 723.0k |

## R&D expense | 7.2m | 12.2m | 14.0m | 16.5m | 17.5m | 19.3m | 18.4m | 20.8m | 16.7m | 17.7m | 9.3m | 8.9m | 7.6m | 9.7m | 9.1m | 9.7m |

## General and administrative expense | 8.5m | 16.8m | 13.8m | 12.6m | 12.3m | 12.6m | 13.7m | 11.3m | 9.6m | 15.2m | 10.7m | 8.0m | 5.8m | 5.4m | 4.9m | 5.6m |

## Operating expense total | 15.9m | 29.1m | 28.0m | 32.1m | 30.2m | 32.1m | 32.9m | 32.3m | 26.4m | 33.1m | 20.1m | 17.0m | 13.5m | 15.1m | 29.1m | 15.4m |

## EBIT | (15.6m) | (27.7m) | (26.7m) | 7.5m | (27.5m) | (31.0m) | (32.0m) | 4.1m | (19.1m) | (28.7m) | (19.3m) | 5.3m | (11.8m) | (4.3m) | (14.0m) | (14.8m) |

| (4304%) | (1961%) | (1986%) | 19% | (1007%) | (2821%) | (3315%) | 11% | (259%) | (647%) | (2562%) | 24% | (690%) | (41%) | (2284%) | (2043%) |

## Interest expense | 316.0k | 464.0k | 467.0k | 472.0k | 494.0k | 597.0k | 1.3m | 714.0k | 677.0k | 634.0k | 534.0k | 488.0k | 457.0k | 288.0k | 297.0k | 308.0k |

## Interest income | 436.0k | |||||||||||||||

## Net Income | (29.0m) | (27.4m) | (28.6m) | (32.6m) | (32.6m) | 3.3m | (19.8m) | (29.2m) | (19.8m) | 5.4m | (12.0m) | (4.0m) | (11.3m) | (14.8m) |

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Cash | 71.6m | 70.9m | 128.2m | 44.0m | 27.2m |

## Accounts Receivable | 235.0k | 2.0m | 282.0k | 378.0k | 4.0k |

## Inventories | 5.1m | 3.4m | 2.8m | 1.5m | 550.0k |

## Current Assets | 80.5m | 80.5m | 135.0m | 55.8m | 46.9m |

## PP&E | 5.5m | 4.6m | 3.7m | 3.0m | 2.4m |

## Total Assets | 93.7m | 92.3m | 144.3m | 63.8m | 54.9m |

## Accounts Payable | 5.1m | 6.4m | 10.6m | 7.2m | 2.6m |

## Short-term debt | 3.2m | 9.0m | 37.4m | 7.9m | 444.0k |

## Current Liabilities | 20.1m | 36.3m | 72.4m | 40.6m | 19.3m |

## Long-term debt | 10.2m | 8.4m | 19.1m | 11.3m | |

## Total Debt | 13.3m | 17.4m | 56.5m | 7.9m | 444.0k |

## Total Liabilities | 37.5m | 96.9m | 56.1m | 38.8m | |

## Retained Earnings | (1.9b) | (2.0b) | (2.1b) | (2.2b) | (2.2b) |

## Total Equity | 42.8m | 38.5m | 47.4m | 7.8m | 16.1m |

## Debt to Equity Ratio | 0.3 x | 0.5 x | 1.2 x | 1 x | 0 x |

## Debt to Assets Ratio | 0.1 x | 0.2 x | 0.4 x | 0.1 x | 0 x |

## Financial Leverage | 2.2 x | 2.4 x | 3 x | 8.2 x | 3.4 x |

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|---|

## Net Income | (43.5m) | (94.2m) | (120.8m) | (53.0m) | |

## Depreciation and Amortization | 1.6m | 1.1m | 990.0k | 831.0k | 717.0k |

## Accounts Receivable | (227.0k) | (2.0m) | 1.6m | (156.0k) | 402.0k |

## Inventories | (3.3m) | 46.0k | (402.0k) | 567.0k | 1.1m |

## Accounts Payable | (5.8m) | 1.5m | 4.4m | (3.0m) | (4.7m) |

## Cash From Operating Activities | (35.8m) | (39.5m) | (95.2m) | (76.7m) | (39.3m) |

## Purchases of PP&E | (1.7m) | (333.0k) | (78.0k) | (137.0k) | (49.0k) |

## Cash From Investing Activities | (1.5m) | (541.0k) | (78.0k) | (137.0k) | (38.0k) |

## Cash From Financing Activities | 59.0m | 36.0m | 152.0m | (7.4m) | 39.0m |

## Interest Paid | 933.0k | 1.9m | 2.1m | 4.4m | 2.0m |

USD | Y, 2018 |
---|---|

## EV/EBIT | -1.1 x |

## EV/CFO | -0.6 x |

## Debt/Equity | 0.1 x |

## Financial Leverage | 1.7 x |

Report incorrect company information

FY, 2016 | |
---|---|

## Phase III Trials Products | 2 |

- Source: SEC Filings

Report incorrect company information